James S Robertson
Overview
Explore the profile of James S Robertson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
613
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manderson T, Loizides U, Dominici M, Robertson J, Balocco R
Lancet
. 2024 Oct;
404(10460):1302-1303.
PMID: 39368836
No abstract available.
2.
Folegatti P, Jenkin D, Morris S, Gilbert S, Kim D, Robertson J, et al.
Vaccine
. 2022 Jun;
40(35):5248-5262.
PMID: 35715352
Replication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A...
3.
Robertson J, Loizides U, Adisa A, Lopez de la Rica Manjavacas A, Rodilla V, Strnadova C, et al.
Vaccine
. 2021 Nov;
40(1):21-27.
PMID: 34844820
International Nonproprietary Names (INN) are assigned by the World Health Organization (WHO) to pharmaceutical substances to ensure global recognition by a unique name. INN facilitate safe prescribing through naming consistency,...
4.
Loizides U, Dominici M, Manderson T, Rizzi M, Robertson J, De Sousa Guimaraes Koch S, et al.
Cytotherapy
. 2021 Apr;
23(5):357-366.
PMID: 33820700
The World Health Organization (WHO) assigns International Nonproprietary Names (INN) to pharmaceutical substances, including advanced therapy medicinal products, to ensure that each substance is globally recognized by a unique name....
5.
Loizides U, Adisa A, Lopez de la Rica Manjavacas A, Robertson J, Balocco R
Lancet
. 2021 Feb;
397(10274):577-578.
PMID: 33549168
No abstract available.
6.
Volkmann A, Williamson A, Weidenthaler H, Meyer T, Robertson J, Excler J, et al.
Vaccine
. 2020 Oct;
39(22):3067-3080.
PMID: 33077299
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. The Modified Vaccinia Ankara (MVA) vector...
7.
Gurwith M, Condit R, Excler J, Robertson J, Kim D, Fast P, et al.
Vaccine
. 2020 Oct;
38(49):7702-7707.
PMID: 33070999
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the...
8.
Condit R, Kim D, Robertson J, Excler J, Gurwith M, P Monath T, et al.
Vaccine
. 2020 Sep;
38(49):7708-7715.
PMID: 32907759
Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety...
9.
Kochhar S, Excler J, Kim D, Robertson J, Fast P, Condit R, et al.
Vaccine
. 2020 Aug;
38(39):6184-6189.
PMID: 32747214
Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector...
10.
Kochhar S, Kim D, Excler J, Condit R, Robertson J, Drew S, et al.
Vaccine
. 2020 Jul;
38(35):5734-5739.
PMID: 32653276
Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key...